Corcoran N - Search Results

1

Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?

Croucher PI, Parker BS, Corcoran N, Rogers MJ. Croucher PI, et al. Among authors: corcoran n. Eur Urol. 2015 Jul;68(1):51-2. doi: 10.1016/j.eururo.2014.10.041. Epub 2014 Nov 11. Eur Urol. 2015. PMID: 25466938 No abstract available.

2

Inorganic selenium retards progression of experimental hormone refractory prostate cancer.

Corcoran NM, Najdovska M, Costello AJ. Corcoran NM, et al. J Urol. 2004 Feb;171(2 Pt 1):907-10. doi: 10.1097/01.ju.0000092859.16817.8e. J Urol. 2004. PMID: 14713851

3

Circulating endothelial cells as biomarkers of prostate cancer.

Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM. Georgiou HD, et al. Nat Clin Pract Urol. 2008 Aug;5(8):445-54. doi: 10.1038/ncpuro1188. Nat Clin Pract Urol. 2008. PMID: 18682720 Review.

4

Paraneoplastic syndromes in prostate cancer.

Hong MK, Kong J, Namdarian B, Longano A, Grummet J, Hovens CM, Costello AJ, Corcoran NM. Hong MK, et al. Nat Rev Urol. 2010 Dec;7(12):681-92. doi: 10.1038/nrurol.2010.186. Nat Rev Urol. 2010. PMID: 21139643 Review.

5

Extraprostatic extension into periprostatic fat is a more important determinant of prostate cancer recurrence than an invasive phenotype.

Kapoor J, Namdarian B, Pedersen J, Hovens C, Moon D, Peters J, Costello AJ, Ruljancich P, Corcoran NM. Kapoor J, et al. J Urol. 2013 Dec;190(6):2061-6. doi: 10.1016/j.juro.2013.06.050. Epub 2013 Jun 29. J Urol. 2013. PMID: 23820055

6

Advances in local and ablative treatment of oligometastasis in prostate cancer.

Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F. Yao HH, et al. Asia Pac J Clin Oncol. 2014 Dec;10(4):308-21. doi: 10.1111/ajco.12256. Epub 2014 Aug 25. Asia Pac J Clin Oncol. 2014. PMID: 25155557 Review.

7

Stimulation of the Neurovascular Bundle Results in Rhabdosphincter Contraction in a Proportion of Men Undergoing Radical Prostatectomy.

Reeves F, Everaerts W, Murphy DG, Kiers L, Peters J, Costello T, Corcoran NM, Costello AJ. Reeves F, et al. Urology. 2016 Jan;87:133-9. doi: 10.1016/j.urology.2015.09.016. Epub 2015 Oct 9. Urology. 2016. PMID: 26456743

8

Disrupting the Status Quo in Prostate Cancer Diagnosis.

Lamb AD, Zargar H, Murphy DG, Corcoran NM, Hovens CM. Lamb AD, et al. Eur Urol. 2017 Feb;71(2):193-194. doi: 10.1016/j.eururo.2016.08.018. Epub 2016 Aug 21. Eur Urol. 2017. PMID: 27554242 No abstract available.

9

Developments in oligometastatic hormone-sensitive prostate cancer.

Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM. Chow K, et al. World J Urol. 2019 Dec;37(12):2549-2555. doi: 10.1007/s00345-018-2542-x. Epub 2018 Oct 31. World J Urol. 2019. PMID: 30382379

10

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. Hamid AA, et al. Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12. Eur Urol. 2019. PMID: 30553611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page